AVITA Medical Inc Dossier - Source-backed chat

AVITA Medical Inc

RCELNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.55

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $11.73Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $362.8M

Enterprise Value $400.3M

Shares Outstanding 32.1M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

AVITA Medical is transitioning from a stabilization phase to execution-led growth, supported by the permanent appointment of Cary Vance as CEO and Jan Stern Reed as Board Chair. The company's core RECELL platform, alongside newly launched products Cohealyx and PermeaDerm, has significantly expanded its addressable market from $455 million to over $3.5 billion. With normalized Medicare reimbursement rates across all MACs and a newly secured 10-year BARDA agreement, AVITA is well-positioned to drive commercial revenue growth and improve operating leverage toward long-term profitability.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.99

Mean target$9.05

High · most bullish analyst$12.11

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$6.0020%

Reimbursement headwinds re-emerge or product mix shifts compress gross margins more than expected, leading to slower revenue growth. Continued cash burn forces the company to draw heavily on its debt facility, increasing interest expenses and delaying profitability.

Base CaseCentral scenario

$8.0050%

Steady execution of the commercial strategy across ~200 U.S. burn and trauma centers, with FY2026 revenue landing within the guided range of $80 million to $85 million. Operating expenses remain disciplined, and cash burn decreases significantly starting in Q2 2026.

Bull CaseUpside scenario

$10.0030%

Rapid commercial adoption of RECELL GO and RECELL GO mini in trauma and smaller wounds, combined with high-margin contributions from Cohealyx and PermeaDerm, drives revenue to the high end of FY2026 guidance ($85 million) and accelerates the path to positive cash flow by late 2026.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Expanded addressable market from $455 million to over $3.5 billion via portfolio diversification (RECELL GO, Cohealyx, PermeaDerm).
Robust gross profit margins (81.7% in Q1 2026) providing strong fundamental unit economics.
Secured 10-year BARDA agreement valued at up to $25.5 million, providing recurring readiness revenue.
Resolution of prior reimbursement headwinds with all seven Medicare Administrative Contractors (MACs) publishing payment rates.

Key Investment Risks

Ongoing net losses ($10.6 million in Q1 2026) and negative operating cash flows.
Relatively tight cash runway with $14.3 million in cash and marketable securities against $48.12 million in debt as of Q1 2026.
Dependence on successful clinician adoption and training for new product lines.

Thesis Invalidation Triggers

Failure to meet the trailing twelve-month (TTM) revenue covenant of $73 million for full-year 2026 under the Perceptive Credit Agreement.
A significant drop in consolidated gross margin below 75% due to unfavorable product mix or inventory write-downs.
Departure of key executive leadership or failure to execute the commercial rollout of RECELL GO.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.